Table of Content

1. GCC Pharmaceutical Market Landscape
1.1 Current Scenario
1.2 GCC Clinical Trials Landscape
1.3 GCC Drug Registration Process
1.3.1 Decentralized & Centralized Drug Registration In GCC
1.3.2 Drug Registration & Regulatory Bodies In GCC


2. GCC Pharmaceutical Market Dynamics & Outlook
2.1 Current Market Overview
2.2 Future Market Opportunities


3. Saudi Arabia Pharmaceutical Market Analysis
3.1 Overview
3.2 Regulatory Framework
3.3 Branded v/s Generic Drugs Availability
3.4 Reimbursement and Insurance Insight


4. Saudi Arabia Clinical Trials Insight By Company, Indication & Phase
4.1 Phase I
4.2 Phase I/II
4.3 Phase II
4.4 Phase II/III
4.5 Phase III
4.6 Preregistration
4.7 Registered


5. Saudi Arabia Marketed Drugs Clinical Insight By Company & Indication



6. UAE Pharmaceutical Market Analysis
6.1 Overview
6.2 Regulatory Framework
6.3 Branded v/s Generic Drugs Availability
6.4 Reimbursement and Insurance Insight


7. United Arab Emirates Clinical Trials Insight By Company, Indication & Phase
7.1 Phase I
7.2 Phase I/II
7.3 Phase II
7.4 Phase II/III
7.5 Phase III
7.6 Preregistration
7.7 Registered
7.8 UAE Marketed Drugs Clinical insight By Company & Indication


8. Qatar Pharmaceutical Market Analysis
8.1 Overview
8.2 Regulatory Framework
8.3 Branded v/s Generic Drugs Availability
8.4 Reimbursement and Insurance Insight


9. Qatar Clinical Trials Insight By Company, Indication & Phase
9.1 Phase II
9.2 Phase III
9.3 Preregistration
9.4 Registered


10. Qatar Marketed Drugs Clinical insight By Company & Indication



11. Oman Pharmaceutical Market Analysis
11.1 Overview
11.2 Regulatory Framework
11.3 Branded v/s Generic Drugs Availability
11.4 Reimbursement & Insurance Insight


12. Oman Clinical Trials Insight By Company, Indication & Phase
12.1 Phase II
12.2 Phase II/III
12.3 Phase III
12.4 Preregistration
12.5 Registered


13. Oman Marketed Drugs Clinical insight By Company & Indication


14. Kuwait Pharmaceutical Market Analysis
14.1 Overview
14.2 Regulatory Framework
14.3 Branded v/s Generic Drugs Availability
14.4 Reimbursement and Insurance Insight


15. Kuwait Clinical Trials Insight By Company, Indication & Phase
15.1 Phase III
15.2 Preregistration
15.3 Registered


16. Kuwait Marketed Drugs Clinical insight By Company & Indication



17. Bahrain Pharmaceutical Market Analysis
17.1 Overview
17.2 Regulatory Framework
17.3 Branded v/s Generic Drugs Availability
17.4 Reimbursement and Insurance Insight


18. Bahrain Clinical Trials Insight By Company, Indication & Phase
18.1 Phase II
18.2 Preregistration
18.3 Registered


19. Bahrain Marketed Drugs Clinical insight By Company & Indication


20. GCC Pharmaceutical Market Drivers & Challenges
20.1 Drivers & Opportunities
20.2 Challenges & Restraints

21. Competitive Landscape

21.1 Local Pharmaceutical Companies

21.1.1 Julphur Pharmaceuticals
21.1.2 SPIMACO Addwaeih
21.1.3 Qatar Life Pharma
21.1.4 Al Mojil Drug Company
21.1.5 Kuwait Saudi Pharmaceutical Company
21.1.6 YIACO Medical Company
21.1.7 Qatar Pharma
21.1.8 Saja Pharmaceuticals
21.1.9 Oman Pharmaceuticals
21.1.10 Taiba Pharmaceuticals
21.1.11 Gulf Biotech
21.1.12 Bahrain Pharma
21.1.13 Neopharma
21.1.14 Planet Pharmacies
21.1.15 Aljazeera Pharmaceutical Industries
21.1.16 Dallah Pharma
21.1.17 Tabuk Pharmaceuticals
21.1.18 CAD Middle-East Pharmaceutical Company
21.1.19 ACDIMA
21.1.20 AL-Mufid Pharmaceuticals

21.2 Multinational Companies

21.2.1 Novartis
21.2.2 Amgen
21.2.3 Eli Lilly
21.2.4 Merck
21.2.5 Pfizer
21.2.6 GlaxoSmithKline
21.2.7 Roche
21.2.8 Takeda Pharmaceuticals
21.2.9 Teva Pharmaceuticals
21.2.10 AstraZeneca
21.2.11 Genentech
21.2.12 Sanofi



List of Figures

Figure 1-1: GCC – Number Of Clinical Trials By Phase, 2024 Till 2030
Figure 1-2: Saudi Arabia – Number Of Clinical Trials By Phase, 2024 Till 2030
Figure 1-3: UAE – Number Of Clinical Trials By Phase, 2024 Till 2030
Figure 1-4: Oman – Number Of Clinical Trials By Phase, 2024 Till 2030
Figure 1-5: Qatar – Number Of Clinical Trials By Phase, 2024 Till 2030
Figure 1-6: Bahrain – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 2-1: GCC – Pharmaceutical Market Size, (US$ Billion), 2023 - 2030
Figure 2-2: GCC – Pharmaceutical Market By Countries (%), 2023
Figure 2-3: GCC – Pharmaceutical Market By Countries (%), 2024
Figure 2-4: GCC – Pharmaceutical Market By Countries (%), 2030

Figure 3-1: Saudi Arabia - Drug Marketing Authorization Process
Figure 3-2: Saudi Arabia: Branded v/s Generic Drugs Market share (%), 2024

Figure 6-1: UAE - Drug Registration & Approval Process
Figure 6-2: UAE – Preference for Generic Drugs

Figure 8-1: Qatar - Drug Registration & Approval Process

Figure 11-1: Oman - Drug Registration Framework Features

Figure 14-1: Kuwait - Drug Registration Framework Features

Figure 17-1: Bahrain - Drug Registration & Approval Process

Figure 20-1: GCC Pharmaceutical Market – Drivers & Opportunities
Figure 20-2: GCC Pharmaceutical Market – Challenges & Restraints

List of Tables

Table 1-1: GCC - Regulatory Overview